Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial
Titel:
Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial
Auteur:
Pignata, Sandro Lorusso, Domenica Scambia, Giovanni Sambataro, Daniela Tamberi, Stefano Cinieri, Saverio Mosconi, Anna M Orditura, Michele Brandes, Alba A Arcangeli, Valentina Panici, Pierluigi Beneditti Pisano, Carmela Cecere, Sabrina C Di Napoli, Marilena Raspagliesi, Francesco Maltese, Giuseppa Salutari, Vanda Ricci, Caterina Daniele, Gennaro Piccirillo, Maria Carmela Di Maio, Massimo Gallo, Ciro Perrone, Francesco